What Moehs does

Moehs Group is a Barcelona-headquartered, privately-held pharmaceutical company founded in 1962 by Sr. Melchor Mallasen Ornat that manufactures Active Pharmaceutical Ingredients (APIs) and provides Contract Development and Manufacturing Organization (CDMO) services to pharmaceutical and biotech customers globally. The company operates seven GMP-compliant production facilities across Spain (Barcelona, Cantabria), Belgium (Anderlecht), France, and Germany, supported by two R&D centers, with a workforce between 501 and 1,000 employees. Its commercial footprint reaches more than 90 countries through direct enterprise sales and an agent network, and the product portfolio comprises more than 200 generic APIs spanning cardiovascular, anesthetic, antidepressant, and antidiabetic therapeutic categories, plus a development-stage pipeline of next-generation molecules. The group also holds a 50% stake in PROTEOS BIOTECH, which represents its only dedicated biotechnology-adjacent interest.

Moehs' technical platform centers on complex small-molecule chemical synthesis with specialized capabilities including HPAPI containment at occupational exposure limits below 1 µg/m³, asymmetric catalytic high-pressure hydrogenation up to 40 bar, cryogenic reactions at temperatures as low as -80°C, chiral resolution and enantioselective synthesis, micronization achieving particle size distribution with D90 below 5 µm, and validated UHPLC-MS/MS nitrosamine detection at ppb levels, alongside mutagenic impurity control demonstrated below 1.0 ppm at 50 kg commercial scale. The group's regulatory position is anchored by 80+ Drug Master Files filed globally, 29 US DMFs registered with the FDA, 16 J-DMFs with PMDA, and 31 Certificates of Suitability (CEPs) granted by the EDQM, with facilities inspected continuously by FDA, PMDA, ANVISA, AEMPS, K-FDA, TGA, and other agencies.

The revenue model combines two streams: (1) catalog sales of 200+ generic APIs to generic-drug manufacturers worldwide on a quote-based, repeat-order basis with associated regulatory documentation (DMF/CEP filings supporting abbreviated new drug applications), and (2) custom CDMO services spanning kilo-lab through Phases I-III clinical and commercial supply, typically structured as multi-year project contracts for pharmaceutical and biotech clients. Go-to-market is enterprise-direct via a commercial team, website inquiries, and active participation in CPHI (Europe, Americas, China, Middle East) and DCAT Week. Pricing is not publicly disclosed and is determined per project by specifications, volume, regulatory documentation, and contract terms.

Name

Moehs

Legal name

MOEHS IBERICA, SL

Website

https://moehs.com

Company type

Private

Founded year

1962

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Moehs Group is a Barcelona-based, privately-held pharmaceutical manufacturer and CDMO producing generic and development-stage Active Pharmaceutical Ingredients (APIs) for global pharmaceutical and biotech clients, operating seven GMP facilities across Europe.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule API Commercial Manufacturing (HLAGAHAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Active pharmaceutical ingredients
• Contract development manufacturing
• Generic API manufacturing
• Pharmaceutical fine chemicals
• Custom API synthesis

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Generic API Product Sales: Moehs manufactures and sells generic Active Pharmaceutical Ingredients (APIs) from their portfolio of over 200 products to pharmaceutical companies worldwide. Revenue is generated through product sales with repeat orders as pharmaceutical clients use APIs in their drug formulations.
2. CDMO Services: Contract Development and Manufacturing Organization services supporting pharmaceutical and biotech companies from early-stage process development through clinical trial supply (Phases I–III) and commercial production. Services include process development, analytical development, clinical supply, and technology transfer. Revenue is project-based, typically multi-year contracts.
3. Pipeline / Custom Manufacturing: Custom synthesis of APIs under development for pharmaceutical clients, including kilo-lab and validation batches for molecules in clinical development. This covers both proprietary molecules for clients and pipeline products at various development stages.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Moehs manufactures and sells Active Pharmaceutical Ingredients (APIs) — including a portfolio of over 200 generic APIs — and provides CDMO (Contract Development and Manufacturing Organization) services for pharmaceutical and biotech clients. The company supports partners across the full product lifecycle, from process and analytical development through clinical trial supply (Phases I–III) and commercial-scale GMP manufacturing, leveraging capabilities such as HPAPI containment, high-pressure hydrogenation, chiral synthesis, cryogenic reactions, and micronization.

Product overview

Moehs is a pharmaceutical fine chemicals company specializing in Active Pharmaceutical Ingredients (APIs) for the global pharmaceutical industry. The company operates as a CDMO (Contract Development and Manufacturing Organization) offering integrated services from development through commercial production. The product portfolio includes generic APIs across multiple therapeutic categories (cardiovascular, local anesthetics, antidepressants, antidiabetics), pipeline products in various development stages, and custom manufacturing services. Key manufacturing capabilities include complex synthesis, HPAPI handling, high-pressure hydrogenation up to 40 bar, chiral synthesis, cryogenic reactions, and particle size control through micronization. The company maintains 7 production facilities across Europe with GMP compliance verified by major regulatory agencies worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Active Pharmaceutical Ingredients (APIs) Portfolio of more than 200 generic APIs manufactured at GMP-compliant facilities across multiple therapeutic categories (cardiovascular drugs, local anesthetics, antidepressants, antidiabetics), sold to pharmaceutical companies worldwide for use in finished dosage forms.
• CDMO Services Integrated Contract Development and Manufacturing Organization services for pharmaceutical and biotech clients covering process development, analytical development, clinical trial manufacturing (Phases I–III), GMP commercial production, and technology transfer, supported by 7 production facilities and 2 R&D centers across Europe.
• Pipeline Products (APIs under development) New active ingredients at various development stages (laboratory, kilo-lab, validation batches) including Abrocitinib, Blarcamesine HCl, Daridorexant, Deucravacitinib, Elagolix Sodium, Elinzanetant, Etrasimod, Fezolinetant, Lasmiditan Succinate, Lemborexant, Lisdexamfetamine Dimesylate, Linzagolix, Metamizol Magnesium Hexahydrate, Sotagliflozin, and Tirbanibulin.
• Custom Manufacturing Custom synthesis and manufacturing services for pharmaceutical APIs, leveraging more than 50 years of experience to support partners from development through commercial production.
• HPAPI Manufacturing Services High-potency active pharmaceutical ingredient manufacturing with asymmetric hydrogenation up to 30 bar, chiral process development, HPAPI containment (OEL below 1 µg/m³), metallic impurity control, micronization, and GMP commercial validation.
• Nitrosamine Analysis and Process Control Services High-sensitivity UHPLC-MS/MS analytical detection and process redesign services for nitrosamine impurity control, validated for ultra-trace detection at ppb levels, including root cause analysis and crystallization optimization for impurity purge.

Quantifiable outcome

• 25.73% reduction in Scope 1 and 2 carbon emissions since 2017
• +5 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core and minor.

• VIDARAcoreStrategic or Co-development Partner · 1 April 2026Moehs Group and VIDARA collaborated on the development of Noradrenaline, an API widely used in intensive care settings. The project progressed through multiple development stages, culminating in the achievement of the Certificate of Suitability (CEP) from the European Pharmacopoeia, confirming the quality of the active ingredient meets required standards.
• PSCI (Pharmaceutical Supply Chain Initiative)minorStrategic or Co-development PartnerMoehs Group complies with the principles promoted by the Pharmaceutical Supply Chain Initiative (PSCI), which establishes ethical, safety, and environmental standards for responsible pharmaceutical supply chain management.
• Aula d'Extensió Universitària de RubíminorOthersMoehs collaborates annually with the Aula d'Extensió Universitària de Rubí, an organization dedicated to bringing knowledge and culture to adults in the city. Moehs supports educational and cultural activities including conferences, cultural outings, and training activities.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Piramal Pharma Solutions: India-headquartered global CDMO with API development and manufacturing capabilities across complex chemistry, HPAPI, and chiral synthesis — competes with Moehs in cost-sensitive generic and CDMO tenders.
• Hovione: Portuguese privately held small-molecule API CDMO with comparable capabilities in complex chemistry, particle engineering, and HPAPI handling. Closely comparable in size, geographic footprint (EU + global), and customer base.
• Siegfried Holding: Swiss-listed API and CDMO with European manufacturing sites serving global pharma — directly comparable in offering (small-molecule APIs, CDMO services, regulatory documentation across DMFs/CEPs).
• Recipharm: Swedish CDMO with pan-European manufacturing and API capabilities, serving similar generic and innovator pharma clients with CDMO services.
• Dishman Carbogen Amcis: India-based CDMO providing API development, HPAPI manufacturing, and contract synthesis services — directly comparable to Moehs in custom API manufacturing for global pharma customers.
• Curia (formerly AMRI): Global CDMO offering small-molecule API development and manufacturing alongside biologics services — competes with Moehs in small-molecule CDMO project work for pharma and biotech clients.
• Cambrex: US-headquartered small-molecule API CDMO owned by Carlyle, offering process development, analytical services, and commercial API manufacturing comparable to Moehs' CDMO offering.
• Euroapi: Sanofi spin-off focused on small-molecule API manufacturing and CDMO services across multiple therapeutic categories — comparable product portfolio and European manufacturing footprint.
• Aenova Group: German privately held CDMO with multiple European manufacturing sites producing APIs and finished dosage forms — overlaps Moehs in contract API manufacturing and European-based pharma services.

Broad incumbents

• Johnson Matthey Health: Diversified UK-listed company whose Health division supplies APIs and pharmaceutical services; broader portfolio than Moehs but overlapping in small-molecule API manufacturing and CDMO offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/moehsgroup
• LinkedInlinkedin.com/company/moehs-iberica-s.l./?viewAsMember=true

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moehs